Camurus' Full Year Report 2022

Fluidcrystal Injection Depot 1

Camurus' Full Year Report for 2022 was published on February 14. 2022 was the first profitable year for Camurus, driven by strong sales growth.

"We ended the year with a fourth quarter with excellent performance across the organization, strong sales momentum, positive operating results, and continued pipeline progress. Camurus reported full year profitability for the first time while also investing half a billion SEK in our R&D pipeline", says Fredrik Tiberg, President & CEO.

Read the full report on Camurus' website: 

Camurus’ Full Year Report 2022 - Camurus

Latest news


Another break-through order for ISEC

ISEC Monitoring Systems has received three substantial and strategically important orders during the last year, amou…

Read more


Camurus' Interim Report Second Quarter 2020

”For the fourth quarter in a row, we saw Buvidal® sales growth of more than 50%”

Read more


Positive results from Phase 2 study

Positive results from Phase 2 study of once-weekly FluidCrystal® formulation of setmelanotide in healthy volunteers…

Read more


Camurus raises full year 2020 revenue guidance

The improvements are driven by increasing market shares of Buvidal® for treatment of opioid dependence in Europe and…

Read more


Camurus Interim Report January-March 2020

”The number of patients treated with Buvidal® increased by 90 percent in the quarter”

Read more